Oxurion NV has entered into a global license agreement with Inceptua SA for the commercialization of JETREA. JETREA is a pharmacological vitreolysis therapy approved for treatment of symptomatic vitreomacular adhesion or vitreomacular traction. The EU Marketing Authorization and global distribution rights will be transferred to the Inceptua Group during 2020, and will vary by region. In Europe, the Marketing Authorization transfer is expected to be completed by Summer 2020.